In mice and other sensitive species, PPAR␣ mediates the induction of mitochondrial, microsomal, and peroxisomal fatty acid oxidation, peroxisome proliferation, liver enlargement, and tumors by peroxisome proliferators. In order to identify PPAR␣-responsive human genes, HepG2 cells were engineered to express PPAR␣ at concentrations similar to mouse liver. This resulted in the dramatic induction of mRNAs encoding the mitochondrial HMG-CoA synthase and increases in fatty acyl-CoA synthetase (3-8-fold) and carnitine palmitoylCoA transferase IA (2-4-fold) mRNAs that were dependent on PPAR␣ expression and enhanced by exposure to the PPAR␣ agonist Wy14643. A PPAR response element was identified in the proximal promoter of the human HMG-CoA synthase gene that is functional in its native context. These data suggest that humans retain a capacity for PPAR␣ regulation of mitochondrial fatty acid oxidation and ketogenesis. Human liver is refractory to peroxisome proliferation, and increased expression of mRNAs for the peroxisomal fatty acyl-CoA oxidase, bifunctional enzyme, or thiolase, which accompanies peroxisome proliferation in responsive species, was not evident following Wy14643 treatment of cells expressing elevated levels of PPAR␣. Additionally, no significant differences were seen for the expression of apolipoprotein AI, AII, or CIII; medium chain acyl-CoA dehydrogenase; or stearoyl-CoA desaturase mRNAs.
A variety of compounds designated as peroxisome proliferators elicit pathological changes in the livers of sensitive species. The effects of exposure include the proliferation of peroxisomes, hepatomegaly, and the development of carcinomas (1) (2) (3) (4) . Peroxisome proliferation follows the extensive induction of peroxisomal and microsomal enzymes that are involved in fatty acid oxidation, and it is thought that increased production of reactive oxygen species generated by these enzymes could contribute to the carcinogenicity of peroxisome proliferators seen in rats and mice. In contrast to sensitive species, guinea pigs and primates appear to be resistant to the adverse consequences of peroxisome proliferator exposure, whereas other species exhibit intermediate effects (5, 6) . Unlike isolated hepatocytes and tumor-derived liver cell lines from rats and mice, human hepatocytes do not exhibit peroxisome proliferator-dependent peroxisome proliferation or induction of the peroxisomal and microsomal enzymes that contribute to fatty acid oxidation (7) (8) (9) (10) .
In mice, the targeted disruption of the gene for the peroxisome proliferator-activated receptor ␣ (PPAR␣) 1 prevents the pathological changes and carcinogenicity resulting from peroxisome proliferator exposure (11, 12) . PPAR␣ is a ligand-activated transcription factor of the nuclear hormone receptor superfamily that binds as a heterodimer with the retinoid X receptor to specific enhancer elements in target genes. Response elements for PPAR␣ have been identified in the genes encoding the microsomal P450 -hydroxylases and components of the peroxisomal long chain fatty acid ␤-oxidation pathway including the long chain fatty acyl-CoA oxidase (ACO1), the enoyl-CoA hydratase (ECH1), and the 3-oxoacyl-CoA thiolase (ACAA1) (reviewed in Ref. 13 ). These enzymes are induced Ͼ10-fold by peroxisome proliferators in rats and mice (reviewed in Ref. 14) . However, it is not known if these genes are regulated by PPAR␣ in humans.
Fatty acids and peroxisome proliferators are ligand agonists for PPAR␣ (15, 16) , and there is increasing evidence that PPAR␣ plays a central role in fatty acid homeostasis by regulating the degradation of fatty acids by mitochondrial as well as by peroxisomal and microsomal fatty acid oxidation (reviewed in Ref. 13 ). In addition, PPAR␣ contributes to the maintenance of energy balance by regulating the expression of enzymes that participate in mitochondrial fatty acid oxidation and the for-mation of ketone bodies from fatty acids in the fasted state (17) (18) (19) . The potential role of PPAR␣ in the regulation of mitochondrial capacity for fatty acid oxidation and ketogenesis in human liver has not been adequately addressed.
Several studies indicate that the expression level of PPAR␣ in human liver (20, 21) is much lower than in mouse liver, and it has been suggested that this difference could contribute to the lack of peroxisome proliferation and subsequent pathologic effects. PPAR␣ agonists are used therapeutically for lowering serum triglycerides, and these hypolipidemic effects observed in humans are known to be mediated by PPAR␣ in other species (22) , suggesting a role for PPAR␣ in the regulation of at least some aspects of lipid metabolism in humans (3) . The differences between rodents and humans in response to peroxisome proliferator exposure could reflect differences between species in the spectrum of target genes regulated by PPAR␣. However, the identification of human target genes has been hampered by the lack of detectable PPAR␣-mediated responses in isolated human hepatocytes or in liver-derived cell lines.
The present study was designed to test whether elevated expression of PPAR␣ in the human hepatoma-derived cell line, HepG2, would unmask PPAR␣-responsive human genes. Several stable cell lines were generated by transfection of HepG2 cells with human PPAR␣ expression vectors. HepG2 cells were selected because they have been studied extensively in relation to lipoprotein metabolism and fatty acid oxidation. Although peroxisomes are present in HepG2 cells and can oxidize fatty acids, treatment with peroxisome proliferators does not induce peroxisomal fatty acid oxidation in this cell line (8, 23) . The level of PPAR␣ mRNA expression in HepG2 cells is roughly 3-fold lower than the values seen for human liver (20) , and transient transfection studies in HepG2 cells using reporter genes under the control of PPAR response elements (PPREs) indicate that significant peroxisome proliferator-dependent reporter expression is evident only when a PPAR␣ expression vector is co-transfected with the reporter construct (20, 24) .
Stable transformants expressing the mouse PPAR␣-E282G mutant were also generated. This mutant contains a glycine substitution for glutamate at position 282, which results in a significantly reduced ligand-independent transactivation relative to the wild type receptor (25) and a reduced affinity for a number of ligands (15, 26) . However, PPAR␣-E282G exhibits similar efficacy as the wild type when activated by PPAR␣ agonists such as Wy14643 (25) . Therefore, this mutant provides a clearer indication of peroxisome proliferator-dependent gene regulation than may be evident using wild-type human PPAR␣.
The results presented here demonstrate that elevated expression of PPAR␣ in HepG2 cells increases the expression of genes encoding several enzymes that catalyze branch points or rate-limiting steps in the utilization of fatty acids for the formation of ketone bodies. The PPAR␣-responsive human genes include the long chain fatty acyl-CoA synthetase (ACS), carnitine palmitoyl acyl-CoA transferase 1A (CPT1A), and the mitochondrial HMG-CoA synthase (HMGCS2). In contrast, the expression of the rate-limiting enzyme of the peroxisomal fatty acid ␤-oxidation pathway, ACO1, and other components of this pathway do not appear to be affected by increased PPAR␣ levels.
MATERIALS AND METHODS

Generation of Stable Cell Lines
Expressing PPAR␣-HepG2 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) containing 10% fetal bovine serum (Summit, Ft. Collins, CO). The human PPAR␣ or mouse PPAR␣-E282G cDNAs were inserted into the pcDNA3.1 vector (InVitrogen, Carlsbad, CA). The PPAR expression vectors and empty pcDNA3.1 plasmid were each transfected into HepG2 cells using a modified calcium phosphate co-precipitation method (27) . Geneticin (G418) (Life Technologies) was used at a final concentration of 500 g/ml to select and maintain positive transformants. The cells were given fresh medium containing G418 every 2-3 days to ensure that an adequate active concentration of G418 was present in the culture medium. A microplate dilution technique was performed to purify transformants. In order to simplify the clone designations throughout, the following nomenclature has been used: hPPAR␣-expressing cell lines 251 and 252 are designated as hPPAR␣1 and hPPAR␣2, respectively. The mouse PPAR␣-E282G-expressing transformants 15 and 16-13 are designated as mPPAR␣G1 and mPPAR␣G2. The wild type HepG2 cells (not transfected) are designated as HepG2, and cells transfected with empty pcDNA3.1 vector that are resistant to G418 are designated as pcDNA throughout.
Transient Transfections-Upper and lower oligonucleotides that had overlapping, complementary 3Ј-ends and that together encompassed nucleotides 1302-1440 of the reported promoter sequence for the human HMGCS2 gene (GenBank TM accession number U81851) were annealed, extended, and amplified using Pfu DNA polymerase (Stratagene, La Jolla, CA). The resulting PCR fragment was gel-purified and inserted into the SmaI site of p19dLuc to generate the pLuc-HMGP reporter construct. For the reporter constructs containing mutations, pLuc-HMGM1 and pLuc-HMGM2, oligonucleotides containing specific mutations that disrupt either the putative PPAR A/T-rich binding site or the RXR binding site (Fig. 8A ) were used as described above. The reporter construct containing the heterologous Herpes simplex thymidine kinase promoter, pLuc-TK-HMG, was generated by inserting annealed, complementary oligonucleotides corresponding to the putative human HMGCS2 PPRE (upper strand, agctCTAAAACTGGGT-CAAAGGGCTCAC; lower strand, agctGTGAGCCCTTTGAC-CCAGTTTTAG) into the HindIII site of pLuc-TK. Lowercase letters indicate single strand overhangs used for cloning. The mutant reporter construct pLuc-TK-HMGM was generated as above using the human HMGCS2 mutant element (Fig. 8B) . The authenticity of the constructs was verified by sequence analysis. The pLuc-TK-ACO-AB, pLuc-TK-Z, or pLuc-TK reporter constructs have been described previously (27) . Each luciferase reporter construct was transfected (2 g/well for 24-well plates; 5 g/well for six-well plates) into HepG2 cells, pcDNA control, or PPAR-transformed cell lines using a modified calcium phosphate coprecipitation method (27) . A ␤-galactosidase reporter construct (pCMV-␤; CLONTECH, Palo Alto, CA) was co-transfected (0.2 g/well for 24-well plates or 0.5 g/well for six-well plates) and used to monitor transfection efficiency. After 16 -24 h of incubation with DNA, the cells were washed with Dulbecco's modified Eagle's medium and incubated with fresh medium containing 500 g/ml G418 and either 50 M Wy14643 or an equivalent volume of vehicle (EtOH) for another 20 -24 h. Luciferase and ␤-galactosidase activities were then analyzed as described (27) . The luciferase activity for each well was normalized to the ␤-galactosidase activity obtained from the same well. Triplicate transfections were carried out for each treatment in each independent transfection experiment, and at least three separate transfection experiments were performed for each cell line.
Preparation of Cell Lysates for Western Blots and Enzyme AssaysHepG2 cells and pcDNA or PPAR transformants were each seeded into T75 flasks in Dulbecco's modified Eagle's medium at a cell density that would reach ϳ60% confluence after overnight culture. After 24 h, the cells were treated with 50 M Wy14643 or EtOH. The medium was replaced with fresh medium containing Wy14643 or solvent alone after another 24 h. After exposure to drug for 48 h, the cells were washed with Dulbecco's phosphate-buffered saline (Life Technologies) and trypsinized. For SDS-polyacrylamide gel electrophoresis and Western blots, the trypsinized cells were suspended in phosphate-buffered saline containing 0.1 mM EDTA and 10% glycerol. Complete protease inhibitor mixture (Roche Molecular Biochemicals) was included prior to sonication twice for 15 s each at 4°C. The sonicated lysates were treated with 0.1% Nonidet P-40, and following a 30-min incubation, they were first centrifuged at 15,000 ϫ g for 10 min and then centrifuged at 235,000 ϫ g for 30 min at 4°C. The final supernatant was used for immunoblot analysis. Protein concentrations were determined with the Pierce BCA reagent using bovine serum albumin as the standard. Cell lysates (100 g of protein/sample) were loaded onto 8% SDS-polyacrylamide gels, electrophoresed, and transferred electrophoretically to nitrocellulose membranes. The level of PPAR␣ expression was quantified by developing the transfer blot sequentially with rabbit anti-mouse PPAR␣ (25) and 125 I-labeled Protein A (ICN, Costa Mesa, CA) prior to analysis using a PhosphorImager SI (Molecular Dynamics, Inc., Sunnyvale, CA).
For enzyme activity assays, trypsinized cells were suspended in 10 mM Tris, pH 7.4, containing 0.25 M sucrose, 1 mM EDTA, 2 M phenyl-methylsulfonyl fluoride, and 2 M 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride. Whole cell homogenate was obtained using a Radnoti glass wall tissue grinder (Radnoti, Monrovia, CA). After 20 up-down strokes, the homogenate was centrifuged at 550 ϫ g for 5 min at 4°C to remove unbroken cells and nuclei. The resulting supernatant represents a "crude lysate" that was aliquoted and stored at Ϫ80°C until analysis. The peroxisomal palmitoyl-CoA oxidase activity in the crude lysate was determined by using palmitoyl coenzyme A ( [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]palmitoyl-labeled) (55 mCi/mmol) (American Radiolabeled Chemical, St. Louis, MO) as the substrate in the presence of 2 mM KCN as described by Lazarow (28) . The mitochondrial HMG-CoA synthase activity in crude lysates was analyzed using the method described by Quant et al. (29) with minor modifications. The buffer system used was modified to 50 mM Tris, pH 8.2, and 1 mM EDTA rather than 50 mM Tris, pH 8.0, with 10 mM MgCl 2 in order to minimize the contribution of cytosolic HMG-CoA synthase activity (30) . The absorption coefficient of acetoacetyl-CoA is 3.6 ϫ 10 3 M Ϫ1 cm Ϫ1 under these conditions. Reverse Transcription and PCR Amplification-HepG2 cells and the stable transformants were cultured and treated with EtOH or 50 M Wy14643 for 48 h as described above. Total RNA was isolated from cells using the RNAgents RNA purification kit (Promega, Madison, WI), and 10 g of total RNA were utilized for reverse transcription using a combination of random and oligo(dT) primers (200 ng each) with Moloney murine leukemia virus reverse transcriptase (Stratagene, La Jolla, CA). For PCR, specific primer sets were synthesized (Table I ) and used for assessment of PPAR␣ and PPAR␣ target gene mRNA levels. As the predicted size of the amplified cDNAs (300 -500 nucleotides) and the T m values for the primers were similar, uniform conditions were applied for the amplification of all cDNAs. The amplification conditions were as follows: one cycle of denaturing at 94°C for 2 min, annealing at 56°C for 1 min 30 s, and extension at 72°C for 1 min. This was followed by 25 cycles of denaturing at 94°C for 30 s, annealing at 56°C for 1 min 30 s, and extension at 72°C for 1 min. The reaction products were analyzed on 1% agarose gels and visualized by ethidium bromide staining.
RNase Protection Assays-PCR-amplified cDNA fragments corresponding to PPAR␣ and target genes were subcloned into pBS-KS(ϩ), sequenced to confirm their authenticity, and used to generate antisense riboprobes. The human ␤-actin probe used as an internal control has been described previously (20) . The region that is spanned by each riboprobe corresponds to the primer set location as listed in Table I . Transcription was carried out in the presence of [ 32 P]CTP (20 mCi/ml, 800 Ci/mmol) using either T3 or T7 RNA polymerase (Stratagene, La Jolla, CA). Following in vitro transcription, the reaction mixture was electrophoresed through 5% acrylamide, 6 M urea gels, and the probes were retrieved from gel slices with elution buffer (RPAII kit, Ambion, Austin, TX). For hybridization, 10 g (target genes) or 20 g (PPAR␣) of total RNA were combined with 4 ϫ 10 4 cpm of gel-purified specific probe and 2 ϫ 10 4 cpm of ␤-actin probe that was generated at a lower specific content. The samples were incubated at 42°C for 18 h and then subjected to RNase digestion for 45 min at 37°C using a 33-fold dilution of RNase A/RNase T1 mix (RPAII kit; Ambion). Protected fragments were separated on 5% acrylamide, 6 M urea gels and analyzed with a Molecular Dynamics PhosphorImager.
Electrophoretic Mobility Shift Assay (EMSA)-Escherichia coli lysates containing expressed mPPAR␣ and RXR-MBP (31) were analyzed for binding to 32 P-labeled double-stranded oligonucleotides by EMSA as previously described (27) . When supershift assays were performed, 1 l of anti-mPPAR␣ serum or preimmune serum was added to the reaction. After a 30-min incubation at room temperature, the reactions were loaded onto a 4% polyacrylamide (37.5:1) gel containing 0.5ϫ TBE and 1.25% glycerol, and the samples were electrophoresed at 16 mA for 100 min at room temperature. The dried gel was analyzed using a Molecular Dynamics PhosphorImager, model SI.
RESULTS
Expression of PPAR␣ in Stable Transformants of HepG2
Cells-HepG2 cells were transfected with either the pcDNA3.1 expression vector or with the vector harboring the cDNA for either hPPAR␣ or mPPAR␣-E282G. The PPAR␣ transformants were enriched by G418 selection. Several cell lines were cloned from pools of hPPAR␣ transformants by dilution in microplates. Individual wells of the microplate were examined microscopically to identify those containing single cells that were then expanded to produce cloned cell lines. The level of transactivation of a luciferase reporter construct containing the PPRE from the rat acyl-CoA oxidase gene and the herpes simplex thymidine kinase promoter, pLuc-TK-ACO-AB, provided an initial assessment of increased PPAR␣ expression levels in each cell line. Several stable lines that exhibited significant transactivation of the transiently transfected reporter relative to both HepG2 and pcDNA controls were selected for further analysis. The results of the transient transfection assay for two examples of human PPAR␣ clones are shown in Fig. 1 . Both of the hPPAR␣ transformants exhibit relatively strong ligand-independent transactivation of the transiently transfected reporter construct, which is consistent with the phenotype exhibited by the human receptor in transient co-transfection assays with the reporter (20) . This transactivation is enhanced by roughly 2-fold or less when Wy14643, a PPAR␣ agonist, is included in the culture medium. No effect is seen for the reporter construct lacking the PPRE, pLuc-TK. A significantly lower ligand-independent transactivation of the reporter construct is evident for mPPAR␣G1 cells; however, these cells exhibit similar levels of ligand-dependent activation of reporter transcription to those seen for the hPPAR␣ transformants (Fig. 1) . As a result, Wy14643 treatment of the mPPAR␣G1 cells elicits a 30-fold response in the expression of the reporter compared with the roughly 2-fold or lower liganddependent responses seen for the hPPAR␣ transformants. These differences are consistent with the results of previous comparisons between the mutant and wild-type PPAR phenotypes (25) .
PPAR␣ protein is readily detected by immunoblotting in those cell lines stably expressing PPAR␣ (Fig. 2) . In contrast, PPAR␣ was not detected under these conditions using equivalent amounts of protein lysate from the control cells or from human liver. The amount of protein detected by immunoblotting in the hPPAR␣ and mPPAR␣G transformants is similar to that seen for equivalent amounts of protein lysate prepared from mouse liver.
Elevated PPAR␣ Expression Elicits Increased Transcription of Endogenous Genes-Peroxisome proliferators have been
shown to regulate the expression of HMGCS2, CPT1A, and ACS in other species (32) (33) (34) . In the PPAR␣ stable transformants, the most dramatic effect was seen on the expression of HMGCS2. In HepG2 and pcDNA control cells, mRNA corresponding to HMGCS2 was not observed by RT-PCR or RNase protection assays and remained undetectable following Wy14643 treatment (Fig. 3) . In contrast, HMGCS2 mRNA was readily detectable in the hPPAR␣-overexpressing transformants, and the mRNA levels were further increased 2-fold by Wy14643 treatment. Increased amounts of HMGCS2 mRNA were also observed in the mPPAR␣G1 transformant following treatment with Wy14643, whereas little or no mRNA was detected in the absence of the agonist (Fig. 3) , which is consistent with the phenotypic differences between wild-type PPAR␣ and mPPAR␣-E282G. Increased HMGCS2 enzyme activity was also observed in hPPAR␣-overexpressing transformants relative to HepG2 and pcDNA control cells (Fig. 4) . In the absence of Wy14643, the enzyme activity obtained from mPPAR␣G1 cell lysates was similar to the basal levels observed in HepG2 and pcDNA transformed cells. However, a significant induction of HMGCS2 enzyme activity was observed when the mPPAR␣G1 cells were exposed to Wy14643. These results indicate that elevations of HMGCS2 mRNA levels lead to increases in HMGCS2 enzyme activity. CPT1A and ACS mRNA levels are also elevated in the PPAR␣ transformants. The expression of CPT1A mRNA was elevated 2-4-fold in the hPPAR␣ transformants and in the mPPAR␣G1 transformant following treatment with Wy14643 as judged by RNase protection assays (Table II and Fig. 5 ). These results suggest that the human CPT1A gene is also PPAR␣-responsive. Human ACS mRNAs were elevated 3-8-fold (Table II) in the hPPAR␣ transformants and in the mPPAR␣G1 transformant following exposure to Wy14643 (Fig.   5 ). These results demonstrate that human genes encoding enzymes that catalyze branch points or rate-limiting steps in the production of ketone bodies from fatty acid oxidation during starvation have retained PPAR␣ responsiveness.
The effect of elevated PPAR␣ levels on the expression of human genes encoding the liver fatty acid-binding protein (FABP1) and components of the peroxisomal and microsomal fatty acid oxidation pathways was also examined, since these pathways have been shown to be regulated by PPAR␣ in other species. The rate-limiting enzyme in the peroxisomal ␤-oxidation of long chain, saturated fatty acids is ACO1, one of two fatty acyl-CoA oxidases in peroxisomes. The other, ACO2, oxidizes branched chain fatty acids. The levels of the ACO1 mRNA in the human PPAR␣ transformants were elevated roughly 2-fold over the control cells (Table II) , and further increases were not apparent after treatment with Wy14643. In contrast, the ACO1 mRNA levels were not elevated in the mPPAR␣G1 transformant even after Wy14643 treatment (Fig. 5) . These results suggest that the modest increase in ACO1 mRNA levels that are not enhanced by agonist may reflect an indirect effect of higher PPAR␣ levels. When ACO2 mRNA levels were assessed, no significant differences were observed between control cells and the PPAR␣ transformants (results not shown). The second enzyme in the peroxisomal long chain fatty acid oxidation pathway, ECH1, was only marginally elevated in the hPPAR␣ transformants (about 2-fold; Table II), and no effect was seen in the mPPAR␣G1 transformant in the presence or absence of Wy14643 (Fig. 5 ). Significant elevations of mRNAs encoding the third enzyme of the peroxisomal fatty acid pathway, ACAA1, were not seen. The level of human FABP1 mRNA was elevated ϳ2-3-fold in the hPPAR␣ transformants relative to the levels seen in HepG2 cells and the pcDNA control transformant (Table II) . However, FABP1 mRNA levels were not significantly elevated in the mPPAR␣G1 transformant or increased by treatment with Wy14643 (Fig. 5) .
PPAR␣ has also been shown to regulate the expression of genes encoding the microsomal cytochrome P450 fatty acid -hydroxylases of the 4A subfamily in other species (35, 36) . To date, only one human P450 4A, CYP4A11, has been characterized. RT-PCR analysis did not detect the mRNA for this enzyme in HepG2 cells or in the PPAR␣ transformants in the presence or absence of Wy14643. Recently, a variant CYP4A11 gene was identified in the human genome that is thought to be a polymorphic form (37) . A specific primer set for this new sequence was also tested. Messenger RNA corresponding to this putative variant was not detected. Thus, we could not assess whether CYP4A11 is regulated by PPAR␣.
The peroxisomal palmitoyl CoA oxidase activity in cell lysates prepared from the cell lines was also characterized (Fig.  6 ). The rate of cyanide-insensitive fatty acid oxidation was 2-3-fold higher in both hPPAR␣ cell lines that exhibited elevated levels of the ACO1 mRNAs. However, no increases in enzyme activity were seen when the cells were treated with Wy14643. In addition, no increases over control cells were seen for the mPPAR␣G1 cells in the presence or absence of Wy14643.
Although the hypolipidemic effect of PPAR␣ agonists is largely thought to reflect the induction of lipoprotein lipase in extrahepatic tissues, studies using isolated, perfused rat livers indicate that the secretion of triglycerides from liver decreases when ketogenesis increases in response to clofibrate. The reciprocal relationship between ketogenesis and triglyceride secretion was attributed to a reduction in the availability of fatty acids for triglyceride synthesis resulting from increased oxidation of fatty acids (38) . Thus, changes in the secretion of triglycerides from the liver could also contribute to the lipid-lowering effects of fibrates. The observation that PPAR␣ regulates the expression of mitochondrial fatty acid oxidation and ketogenesis suggests that this pathway could contribute to the hypolipidemic effects of PPAR␣ agonists in humans.
The changes in liver secretion of triglyceride elicited by clofibrate could also reflect direct regulation of triglyceride and lipoprotein secretion by PPAR␣ in the liver. PPAR␣ agonists are reported to modestly induce apolipoprotein A-I and A-II mRNAs and suppress apolipoprotein C-III mRNAs in human hepatocytes (39 -41) . Resulting changes in the composition of lipoprotein particles are also likely to increase the catabolism of triglycerides in extrahepatic tissues (42, 43) . RT-PCR analysis using a range of conditions did not detect significant differences in the mRNA levels for these apolipoproteins between the HepG2 or pcDNA controls and the hPPAR␣ or mPPAR␣G transformants. Also, the addition of Wy14643 to the cultures did not have a significant impact on mRNA levels (data not shown). RNase protection assays confirmed the results of the RT-PCR study for apolipoprotein CIII (Table II) . The suppression of apolipoprotein C-III mRNA levels by fibrates in HepG2 cells was reported to be dependent on the serum used in the culture medium (44) , and it is possible that different culture conditions might confer a Wy14643 dependence to the suppression of the apolipoprotein CIII RNAs. Additionally, RT-PCR assays (data not shown) did not demonstrate noticeable differences for mRNAs encoding the mitochondrial medium chain acyl-CoA dehydrogenase or the stearoyl-CoA desaturase 1, which have been reported to be regulated by PPAR␣ in other species (45, 46) . The lipogenic malic enzyme gene is regulated by PPAR␣ in rats (47) . Similar to the results obtained for CYP4A11, mRNA encoding the cytosolic malic enzyme could not be detected in HepG2 cells or the PPAR␣ transformants by RT-PCR, precluding an assessment of the responsiveness of this gene to PPAR␣ regulation in humans.
Identification of a PPRE in the Proximal Promoter of the Human HMGCS2 Gene-The proximal promoter of the rat HMGCS2 gene contains a functional PPRE (33) . Examination of the corresponding region of the human HMGCS2 gene indicated that the essential features of this element were likely to be conserved (Fig. 7) . EMSA experiments performed with this putative human PPRE demonstrated PPAR␣/RXR␣ binding. Inclusion of anti-PPAR␣ antiserum in the EMSA resulted in nearly complete supershifting of the complexes. Doublestranded oligonucleotides corresponding to the human HMGCS2 PPRE that contained mutations were also synthesized. Based on previous studies (27, 31) , disruption of the A/T-rich region in the 5Ј-end of the extended PPRE abrogates PPAR binding and transcriptional activation. As expected, these mutations to the human HMGCS2 PPRE abolished PPAR/RXR heterodimer binding (Fig. 7) . Mutations introduced into the second half site of hHMGCS2 PPRE also interfered with PPAR␣/RXR␣ binding (data not shown). These results suggest that a functional PPRE may be present in the human HMGCS2 gene.
A reporter construct containing a portion of the human HMGCS2 proximal promoter region that encompassed the putative PPRE and included the transcription start site was constructed based on the deletion analysis that identified a PPRE in the rat HMGCS2 gene (33) . This study indicated that a portion of the rat promoter from Ϫ116 to ϩ28 exhibited extensive transactivation by PPAR␣. The corresponding region of the The catalytic rate of palmitoyl-CoA oxidase was determined for three independent preparations of cell lysates obtained from the indicated cell lines. *, rates that differ significantly (p Ͻ 0.01) from the rates obtained for the pcDNA control treated with solvent (EtOH) using a one-tailed Student's t test.
human HMGCS2 promoter, nucleotides Ϫ130 to ϩ8, was inserted into the p19dLuc vector. When this reporter construct was transiently transfected into hPPAR␣-overexpressing cells, significant transactivation was observed (Fig. 8A) . This transactivation was further enhanced when Wy14643 was included in the culture medium. A clear ligand-dependent response was also observed for the mPPAR␣G transformant. As expected, the mutations introduced into the A/T-rich region of HMGCS2 PPRE or the RXR binding site, as described above in the EMSA binding experiments, abolished PPAR␣-mediated transactivation when introduced into the HMGCS2 promoter (Fig. 8A) . When the putative HMGCS2 PPRE was inserted upstream of the herpes simplex thymidine kinase promoter and luciferase reporter gene (pLuc-TK-HMG) and transiently transfected into cells overexpressing hPPAR␣ or mPPAR␣G, the PPRE conferred PPAR␣-and Wy14643-dependent transactivation to the heterologous promoter (Fig. 8B) . As expected, the mutations introduced into the A/T-rich region of HMGCS2 PPRE (pLuc-TK-HMGM) abolished PPAR␣-mediated transactivation (Fig.   8B ). These results indicate that the human HMGCS2 gene contains a functional PPRE in the proximal promoter region.
DISCUSSION
The present study was designed to examine whether human genes encoding enzymes and proteins that control the rate of fatty acid oxidation by mitochondrial, peroxisomal, and microsomal pathways exhibit a capacity for regulation by PPAR␣. Elevated hPPAR␣ levels in HepG2 cells elicited increased expression of three of the genes examined, HMGCS2, CPT1A, and ACS. In each case, the mPPAR␣G1 cells exhibited strong liganddependent responses. However, ligand-specific increases for CPT1A and ACS were not as readily apparent in the hPPAR␣ cell lines. This is concordant with the phenotypic differences seen between hPPAR␣ and mPPAR␣-E282G when PPAR␣ expression plasmids and reporter constructs were used in transient co-transfection assays (20) .
The largest increase mediated by hPPAR␣ was seen for the mitochondrial form of HMG-CoA synthase, which is the ratelimiting enzyme in ketone body formation from fatty acids (48) . HMGCS2 mRNA could not be detected in control cells but was abundantly expressed in stably transformed cells overexpressing hPPAR␣. An increase in PPAR␣-regulated transcriptional activity in response to fatty acid and fibrate agonists has been demonstrated for the rat HMGCS2 gene (33) . In mice, this enzyme is elevated in response to starvation, and this effect is blocked in PPAR␣ null mice. Fed PPAR␣-deficient mice also exhibit reduced levels of HMGCS2 in liver (49) . Taken together, these results indicate that the expression of HMGCS2 in mice is highly dependent on the expression of PPAR␣. Our results suggest that human HMGCS2 is also responsive to regulation by PPAR␣. In contrast, the abundance of mRNAs encoding the cytosolic enzyme, HMGCS1, was not affected by increased expression of PPAR␣ or by treatment with Wy14643 (results not shown).
The rat HMGCS2 gene exhibits a PPRE in the proximal promoter that binds PPAR␣/RXR heterodimers (33) . As shown here, the sequence of the corresponding response element in the human gene is highly similar to the rat PPRE, and the human element exhibits strong PPAR␣/RXR binding. The putative human PPRE confers transactivation by PPAR␣ to a luciferase reporter gene that is under the control of the heterologous TK promoter, indicating that this response element is functional. In addition, this PPRE is active in the context of the natural human HMGCS2 proximal promoter, and mutations that disrupt binding of PPAR␣/RXR to the PPRE block transactivation of both the TK and native promoter reporters by PPAR␣. Taken together, the data suggest that this element could contribute to the dramatic elevation of human HMGCS2 mRNA levels in the hPPAR␣ cell lines.
During periods of fasting, the substrates of HMGCS2, acetylCoA and acetoacetyl-CoA, are produced from the oxidation of fatty acids in liver mitochondria, leading to increased production of ketone bodies for distribution to other tissues. In mice nullizygous for PPAR␣, fasting results in hypoglycemia and liver steatosis, reflecting diminished fatty acid oxidation and ketogenesis in liver (19) . Several aspects of fatty acid oxidation are disrupted in PPAR␣ null mice that include a diminished, constitutive expression of several components of the mitochondrial fatty acid oxidation pathway (17, 50) . These results suggest that, in mice, PPAR␣ is a significant regulator of the mitochondrial capacity for fatty acid ␤-oxidation. The flux of long chain fatty acids through the mitochondrial ␤-oxidation pathway is regulated by CPT1, a component of the long chain fatty acylcarnitine translocases (51) . The activity of CPT1 is modulated by the concentration of malonyl-CoA, a potent inhibitor of the enzyme that is formed in the first committed step of fatty acid synthesis (52) . In addition, CPT1 is induced by peroxisome proliferators in rat liver (32) . The predominant liver enzyme, CPT1A, is one of two variants of CPT1 that have been identified. The other, CPT1B, is found predominantly in muscle and adipose tissue. Although a PPRE has been characterized for the human CPT1B gene (53) (54) (55) , RT-PCR experiments indicated that CPT1B mRNAs were present at low levels in HepG2 cells and were not affected by elevated expression of PPAR␣ in the presence or absence of Wy14643 (results not shown). In contrast, the abundance of CPT1A mRNA was elevated 2-4-fold in the hPPAR␣ transformants and following the treatment of the mPPAR␣G1 cells with Wy14643, suggesting that the human CPT1A gene is also PPAR␣-responsive.
The fatty acyl-CoA substrates for CPT1 are formed by the esterification of free fatty acids to CoA by ACS. ACS is induced by peroxisome proliferators in rat liver, and a PPRE has been identified in the promoter of the rat gene (34) . The expression of human ACS mRNAs was elevated in the hPPAR␣ cell lines and could be augmented further by treatment with Wy14643.
These changes are commensurate with an increased capacity for mitochondrial fatty acid oxidation. Given the importance of adaptive changes in the expression of ACS, CPT1, and HMGCS2 to the maintenance of energy homeostasis during fasting, it is not surprising that the corresponding human genes are also capable of being regulated by PPAR␣.
In contrast, consistent and significant effects of elevated PPAR␣ levels on the expression of genes encoding components of the peroxisomal long chain fatty acid ␤-oxidation pathway, ACO1, ECH1, and ACAA1, were not clearly evident. Effects of 2-fold or less were seen for the two hPPAR␣ cell lines shown in Table II . Examination of a larger panel of cell lines that exhibit elevated expression of human PPAR␣ indicated that the modest elevation of these mRNAs was not consistently seen in other transformants. In addition, a ligand-dependent increase was not seen with the mPPAR␣G1 cells or with either of the two hPPAR␣ cell lines, suggesting that the small differences observed might not be directly attributable to PPAR regulation of these genes in the hPPAR␣ cell lines.
We and others have noted that the expression level of PPAR␣ in human liver is much lower than in mouse liver, and it has been suggested that this difference could contribute to the lack of peroxisome proliferation and subsequent pathologic effects (20, 21) . Like humans, guinea pigs are refractory to peroxisome proliferation and also exhibit lower hepatic expression of PPAR␣ (5) . However, transient transfection of primary cultures of guinea pig hepatocytes with expression vectors for either mouse, guinea pig, or human PPAR␣ conferred increases in the expression of rat acyl-CoA oxidase gene reporter constructs and also in the enzymatic activity of endogenous acylCoA oxidase in response to peroxisome proliferators (56) . These results contrast with our data for the human ACO1 gene in the PPAR␣ HepG2 transformants. Other evidence for the functional impact of lower PPAR␣ levels is apparent in data from mice indicating that the induction of the peroxisomal fatty acid oxidation pathway is lower in extrahepatic tissues that also express lower levels of PPAR␣ (57) . Moreover, the expression of the murine ACO1 gene is elevated in PPAR␣ null mice in response to agonists that are relatively specific for PPAR␦ and PPAR␥. The observed response is lower than that seen for PPAR␣ agonists in wild-type mice and is likely to reflect the relatively low levels of PPAR␦ and PPAR␥ when compared with the level of PPAR␣ in mouse liver (58, 59) . These findings suggest that quantitative differences in PPAR␣ expression alter the extent of enzyme induction and that the relatively high expression of PPAR␣ in mouse liver could contribute to the pathogenicity of peroxisome proliferators in this species.
Our results indicate that increasing the expression of PPAR␣ in HepG2 cells to levels found in mouse liver is not sufficient to confer peroxisome proliferator-responsiveness to the ACO1 gene or the human genes encoding other components of peroxisomal fatty acid oxidation in HepG2 cells. The absence of an effect on this pathway could reflect either of two likely possibilities. First, functional PPREs may not have been conserved in the orthologous human genes during evolution of the species. In this regard, the human ACO1 gene was reported to contain a functional PPRE (60) . However, the functionality of this PPRE has been questioned (61) . Alternatively, differences between HepG2 cells and normal liver in the expression of critical transcription factors or necessary auxiliary proteins could limit the capacity of PPAR␣ to regulate the expression of the genes encoding the peroxisomal fatty acid oxidation pathway. The lack of detectable expression of mRNAs for CYP4A11 or the malic enzyme is clearly indicative of differences in gene expression between HepG2 cells and normal liver. In this respect, the positive effects of PPAR␣ overexpression on the expression of HMGCS2, CPT1A, and ACS can be more readily interpreted than the absence of an effect on peroxisomal fatty acid oxidation.
During fasting or starvation, activation of mitochondrial ketogenic capacity represents an important physiologic regulatory pathway for utilization of existing energy stores through mobilization and catabolism of free fatty acids. The results presented here indicate that human genes encoding key enzymes for mitochondrial fatty acid oxidation and ketogenesis can be regulated by human PPAR␣.
